Real-world comparison of the effects of etanercept and adalimumab on well-being in non-systemic juvenile idiopathic arthritis: a propensity score matched cohort study

Etanercept (ETN) and adalimumab (ADA) are considered equally effective biologicals in the treatment of arthritis in juvenile idiopathic arthritis (JIA) but no studies have compared their impact on patient-repo...

Source: Pediatric Rheumatology - November 14, 2022 Category: Rheumatology Authors: Joeri W. van Straalen, Sytze de Roock, Gabriella Giancane, Alessandro Consolaro, Marite Rygg, Ellen B. Nordal, Nadina Rubio-P érez, Marija Jelusic, Jaime De Inocencio, Jelena Vojinovic, Nico M. Wulffraat, Patricia C. J. Bruijning-Verhagen, Nicolino Ruper Tags: Research article Source Type: research